Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C powder. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
Frequently asked questions
What sector does Staidson Beijing Biopharma (300204) operate in?
Staidson Beijing Biopharma belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Staidson Beijing Biopharma (300204) current stock price?
As of the latest data, Staidson Beijing Biopharma stock price is CN¥25.82, with a previous close of CN¥23.93. Staidson Beijing Biopharma gained CN¥1.89 in the last trading session, representing a 7.9% increase.
What is Staidson Beijing Biopharma (300204) current market capitalization?
Staidson Beijing Biopharma market cap is approximately 13.98 billion.
What is Staidson Beijing Biopharma (300204) Earnings Per Share (EPS)?
The trailing EPS is -CN¥0.18, and the forward EPS is CN¥0.03.
Does Staidson Beijing Biopharma (300204) pay dividends?
No. Staidson Beijing Biopharma does not pay a dividend.
What is Staidson Beijing Biopharma (300204) beta (volatility) score?
Staidson Beijing Biopharma has a beta of 0.436, indicating lower volatility than the overall market.
